Products Ribociclib was approved in the United States, the EU, and many countries in 2017 in film-coated tablet form (Kisqali). Structure and properties Ribociclib (C23H30N8O, Mr = 434.5 g/mol) is present in the drug as ribociclibsuccinate, a pale yellow to yellow-brown crystalline powder. Effects Ribociclib (ATC L01XE42) has antitumor and antiproliferative properties. The effects are … Ribociclib
Products Denosumab is commercially available as a solution for injection in a prefilled syringe (Prolia). The antibody was approved in many countries, in the United States, and in the EU in 2010. Denosumab is also used in tumor therapy (Xgeva). This article relates to osteoporosis treatment. Structure and properties Denosumab is a human IgG2 monoclonal … Denosumab
Products Alpelisib was approved in the United States in 2019 and in many countries in 2020 in film-coated tablet form (Piqray). Structure and properties Alpelisib (C19H22F3N5O2S, Mr = 441.5 g/mol) exists as a white powder. Effects Alpelisib (ATC L01XX65) has antiproliferative and antitumor properties. The effects are due to inhibition of the α-subunit of phosphatidylinositol … Alpelisib
Products Aromatase inhibitors are commercially available in the form of film-coated tablets and coated tablets. The first third-generation agent to be approved in many countries was anastrozole in 1996 (Arimidex, USA 1995). Other drugs are available today. The active ingredients available today all belong to the third generation. Earlier agents such as aminoglutethimide and formestane … Aromatase Inhibitors
